Why Do Metabolic Problems Come Back After Stopping GLP-1 Drugs?

A New Study Offers Clues — and Raises a Bigger Question

A new analysis from the SURMOUNT-4 clinical trial has just been published in JAMA Internal Medicine. It follows people with obesity who lost weight on tirzepatide (a GIP/GLP-1 agonist) for 36 weeks, and then had the medication withdrawn for one year.

The results were striking:

• 82.5% regained at least 25% of the weight they had lost

• About half regained 50% or more

• One in four regained most or all of the lost weight

• And some regained more than 100%

Even more importantly, as weight returned, so did many of their previous health risks:

• blood pressure rose

• insulin and insulin resistance increased

• waist circumference expanded

• triglycerides and cholesterol worsened

• HbA1c and fasting glucose drifted upward within 16 weeks

From the outside, it seems simple: “They regained weight, so their health markers got worse.”

But this explanation leaves something important out.

What the Study Did Not Measure: Muscle Loss

Despite measuring over a dozen metabolic markers, the SURMOUNT-4 trial did not assess body composition.

No DXA.

No MRI.

No CT.

No measurement of skeletal muscle.

This is a critical gap, because multiple previous studies have already shown that GLP-1–based medications consistently produce:

• loss of lean mass,

• including loss of skeletal muscle,

• often accounting for 20–40% of total weight lost.

This has been observed in:

• the STEP semaglutide trials

• the SURMOUNT program

• several independent DXA-based cohort studies

• real-world patient follow-up

So even though SURMOUNT-4 didn’t measure muscle, the broader evidence makes something very clear:

When people lose weight on GLP-1RA therapy, they almost always lose muscle too.

And this missing piece helps explain why metabolic health deteriorates so quickly after the medication is stopped.

Why Muscle Loss Matters More Than Most People Realize

Muscle is not just for strength.

It is our largest glucose reservoir, our primary metabolic buffer, and a key component of metabolic flexibility—the body’s ability to switch between fuels under stress.

When muscle mass declines:

• insulin sensitivity worsens

• glucose tolerance drops

• blood pressure regulation is impaired

• fat regain becomes easier and faster

• stress hormones rely more heavily on amino acids from remaining muscle

• and the whole metabolic system becomes less resilient

This means:

Weight regain after stopping GLP-1 drugs is not just about eating more. It’s also about having less muscle to stabilize the system.

The metabolic rebound may therefore be a symptom of lost metabolic reserve, not simply a return of weight.

Could GLP-1 Drugs Contribute to Sarcopenia? The Mechanism Makes Sense

A growing body of research shows that long-acting GLP-1 and GIP/GLP-1 agonists strongly suppress glucagon—a hormone essential for:

• hepatic glucose production

• amino acid metabolism

• maintaining muscle protein balance

• stress-response energy mobilization

Chronically low glucagon impairs the liver’s ability to clear amino acids.

As amino acids rise in the blood, the body compensates by breaking down skeletal muscle to restore balance — a mechanism sometimes referred to as the “glucagon–aminostasis” axis.

At the same time:

• appetite drops

• protein intake often declines

• mitochondrial efficiency increases (less anabolic drive)

• physical activity may decrease

All of these tilt the system toward net muscle loss.

The biological logic is simple:

If a medication strongly suppresses glucagon for months or years, muscle loss is not a side-effect — it is an expected outcome.

Why This Matters Now

The SURMOUNT-4 study shows that once tirzepatide is stopped:

• glucose control worsens within weeks

• insulin resistance rebounds sharply

• and nearly all cardiometabolic benefits fade within a year

If the body has lost meaningful muscle mass during therapy, this rapid rebound is exactly what we would expect.

Yes, weight regain is part of the story. But weight regain alone cannot explain:

• the immediate rise in HbA1c

• the early spike in fasting glucose

• the rapid increase in insulin

• or the rebound in blood pressure and lipids

These began long before most participants regained large amounts of weight.

Which means:

Sarcopenia — not just weight regain — is likely contributing to the metabolic regression.

Ignoring this could lead to false reassurance and misinterpretation of what GLP-1RA withdrawal truly does to long-term metabolic resilience.

A More Complete Interpretation

To protect long-term health, we must shift the conversation from:

“How much weight did you lose?”

to:

“How much metabolically active lean mass did you preserve?”

“What happened to your metabolic flexibility?”

“Are we trading short-term benefits for long-term muscle depletion?”

The SURMOUNT-4 trial gives us valuable insights — but the absence of body composition data leaves a blind spot. When we overlay this study onto the broader evidence, the pattern becomes clearer:

GLP-1RA therapy may induce a form of medically driven sarcopenia, which makes metabolic rebound nearly inevitable after stopping the drug.

This is not an argument against GLP-1 drugs.

It is an argument for:

• monitoring lean mass

• supporting protein intake

• resistance training

• reconsidering chronic glucagon suppression

• recognizing the bioenergetic cost of thinness

• and not mistaking weight loss for metabolic health.

Final Thought

GLP-1 medicines offer real benefits. But if we want to help people improve their long-term metabolic health—not just their weight—then we must look beyond the scale.

Muscle is the engine of metabolic resilience.

If we lose it, we lose the very foundation of long-term health.

Horn, D. B., Linetzky, B., Davies, M. J., Laffin, L. J., Wang, H., Murphy, M. A., Zimner-Rapuch, S., Lau, E., Arad, A. D., & Lee, C. J. (2025). Cardiometabolic parameter change by weight regain on tirzepatide withdrawal in adults with obesity: A post hoc analysis of the SURMOUNT-4 trial. JAMA Internal Medicine. Advance online publication. https://doi.org/10.1001/jamainternmed.2025.6112

Tippairote, T., Hoonkaew, P., Suksawang, A. et al. Glucagon suppression under GLP-1RA therapy: hidden trade-offs for muscle and resilience. Diabetol Int 17, 2 (2026). https://doi.org/10.1007/s13340-025-00856-4